There is no reasonable evidence to support efficacy of fluvoxamine in prevention of disease deterioration in COVID-19 outpatients: A comment on two recent meta-analyses advocating its use
Trkulja, V. (2023). There is no reasonable evidence to support efficacy of fluvoxamine in prevention of disease deterioration in COVID-19 outpatients: A comment on two recent meta-analyses advocating its use. Journal of Infection, 86. (2), 154-225. doi: 10.1016/j.jinf.2022.11.016
Trkulja, Vladimir. "There is no reasonable evidence to support efficacy of fluvoxamine in prevention of disease deterioration in COVID-19 outpatients: A comment on two recent meta-analyses advocating its use." Journal of Infection, vol. 86, no. 2, 2023, pp. 154-225. https://doi.org/10.1016/j.jinf.2022.11.016
Trkulja, Vladimir. "There is no reasonable evidence to support efficacy of fluvoxamine in prevention of disease deterioration in COVID-19 outpatients: A comment on two recent meta-analyses advocating its use." Journal of Infection 86, no. 2 (2023): 154-225. https://doi.org/10.1016/j.jinf.2022.11.016
Trkulja, V. (2023) 'There is no reasonable evidence to support efficacy of fluvoxamine in prevention of disease deterioration in COVID-19 outpatients: A comment on two recent meta-analyses advocating its use', Journal of Infection, 86(2), pp. 154-225. doi: 10.1016/j.jinf.2022.11.016
Trkulja V. There is no reasonable evidence to support efficacy of fluvoxamine in prevention of disease deterioration in COVID-19 outpatients: A comment on two recent meta-analyses advocating its use. Journal of Infection [Internet]. 2023 February [cited 2024 May 03];86(2):154-225. doi: 10.1016/j.jinf.2022.11.016
V. Trkulja, "There is no reasonable evidence to support efficacy of fluvoxamine in prevention of disease deterioration in COVID-19 outpatients: A comment on two recent meta-analyses advocating its use", Journal of Infection, vol. 86, no. 2, pp. 154-225, February 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:974766. [Accessed: 03 May 2024]
